Divamics Showcases Lead Autoimmune Program DVI-001 and Unveils New Metabolic Program DVI-004 at JPM Week 2026

2026-01-26 - 12:51

SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ — Divamics (DIVAMICS), an AI-driven biotechnology company specializing in high-precision molecular discovery, highlighted the significant advancement of its internal pipeline during the Biotech ShowcaseTM at JPM Week 2026. The company provided updated milestones for its lead autoimmune program, DVI-001, and announced the first disclosure of DVI-004, a promising new metabolic disease program generated